VYGR vs. CABA, ADVM, BLUE, JNCE, CASI, INBX, SANA, NMRA, VIR, and DNA
Should you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Cabaletta Bio (CABA), Adverum Biotechnologies (ADVM), bluebird bio (BLUE), Jounce Therapeutics (JNCE), CASI Pharmaceuticals (CASI), Inhibrx (INBX), Sana Biotechnology (SANA), Neumora Therapeutics (NMRA), Vir Biotechnology (VIR), and Ginkgo Bioworks (DNA). These companies are all part of the "medical" sector.
Voyager Therapeutics (NASDAQ:VYGR) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations.
Voyager Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500.
Voyager Therapeutics has higher revenue and earnings than Cabaletta Bio. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.
Cabaletta Bio has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -2.56%. Voyager Therapeutics' return on equity of -1.28% beat Cabaletta Bio's return on equity.
Voyager Therapeutics received 302 more outperform votes than Cabaletta Bio when rated by MarketBeat users. However, 70.00% of users gave Cabaletta Bio an outperform vote while only 67.32% of users gave Voyager Therapeutics an outperform vote.
In the previous week, Cabaletta Bio had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 4 mentions for Cabaletta Bio and 2 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.58 beat Cabaletta Bio's score of 1.02 indicating that Voyager Therapeutics is being referred to more favorably in the media.
48.0% of Voyager Therapeutics shares are owned by institutional investors. 4.5% of Voyager Therapeutics shares are owned by insiders. Comparatively, 9.9% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Voyager Therapeutics currently has a consensus target price of $18.00, indicating a potential upside of 114.29%. Cabaletta Bio has a consensus target price of $34.33, indicating a potential upside of 236.93%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Voyager Therapeutics.
Summary
Cabaletta Bio beats Voyager Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Voyager Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Voyager Therapeutics Competitors List
Related Companies and Tools
